Curated Resource Center for Small Cell Lung Cancer

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Small Cell Lung Cancer. Accessed November 15, 2022.

The NCCN Guidelines® are the recognized standard for clinical information in cancer care. They are updated frequently with the intent to assist in the decision-making process of individuals involved in cancer care—including physicians, nurses, pharmacists, payers, patients and their families—with the ultimate goal of improving patient care and outcomes.To access the guidelines, registration is required, but free.

Journal of the American Medical Association (JAMA) Oncology. Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care Shared Decision Making in Cancer Care. Accessed November 15, 2022.

A Journal of the American Medical Association article highlighting shared decision-making in cancer care. The article specifically examines the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study for lung and colorectal cancer.

MayoClinic. Current Diagnosis and Management of Small-Cell Lung Cancer. Accessed November 15, 2022.

Journal-based CME activity for internal medicine physicians and other clinicians. The aticle specifically examines:  (1) the clinical features, diagnostic tests, and clinical staging of small cell lung cancer (SCLC), (2) the current standard of care treatment in SCLC, and (3) novel agents under investigation for the therapy of SCLC.

Society of Hospital Medicine (SHM). Improving Care for Hospitalized Patients Newly Diagnosed with Lung Cancer. Accessed November 15, 2022.

This Society of Hospital Medicine has developed a suite of resources to support hospitalists and other clinicians with best practices and evidence-based strategies for conducting patient-centered discussions with lung cancer patients and facilitating good coordination of care.

Academy of Oncology Nurse & Patient Navigators (AONN+)

In the Helping to Expedite Care in Small Cell Lung Cancer Video you will hear best practices on how oncology nurses and navigators can help expedite care for patients with small cell lung cancer. As compainon pieces AONN+ also has available the Lung Cancer Management Checklist and the Lung Cancer Navigator Patient Roadmap. 

American Society of Radiation Oncology (ASTRO)

The ASTRO Academy offers CME cources on small-cell lung cancer, which include management of small-cell lung cancer as well as case studies. Fees are associated with each course. 

Center to Advance Palliative Care (CAPC)

CAPC provides essential tools, training, technical assistance, and connection for all clinicians caring for people with a serious illness.

The LuCa National Training Network

The LuCa National Training Network at the University of Louisville is the nation's first and only non-profit organization dedicated to enhancing provider education on lung cancer care across the continuum.

Patient Assistance & Reimbursement Guide Overview

ACCC's digital Patient Assistance & Reimbursement Guide helps healthcare professionals and patients find the most up-to-date information on the anti-cancer medication assistance and reimbursement programs that are available to help alleviate the financial burden of cancer treatment

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Lung Cancer and Family-Centered Patient Concerns. Accessed November 15, 2022.

This article from PubMed, reviews a qualitative study examining lung cancer patients’ preferences in including their family and caregivers into discussions regarding risk factors, diagnosis, management, and outcomes for their disease.

National Institutes of Health (NIH). National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. Accessed November 15, 2022.

A National Cancer Institute resource for health professionals covering general information, cellular classification, stage information, and standard treatment options for small cell lung cancer.

Institute for Healthcare Improvement. SBAR Tool: Situation-Background-Assessment-Recommendation. Accessed November 15, 2022.

The Institute for Healthcare Improvement provides the SBAR (Situation-Background-Assessment-Recommendation) tool to frame communication between healthcare team members regarding a patient's condition. The tool is accessible as well as an overview and example.

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. Accessed November 15, 2022.

This article published in Advances in Therapy, summarizes current treatment options and emerging data on newer agents and biomarkers for patients with SCLC. Treatment option information looks at various factors that should be considered when choosing a second-line treatment. It also provides evidence-based clinical considerations for oncologists treating patients with relapsed ES-SCLC.

Integra Connect. Burden of Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated with Chemotherapy in a Community Oncology Setting. Accessed November 15, 2022.

This resource is a poster presentation examining the burden of myelosuppression hemalotogic adverse events in patients with extensive-stage small cell lung cancer who have been treated with chemotherapy.

American Society of Clinical Oncology. Journal of Clinical Oncology. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database. Accessed November 15, 2022.

A Journal of Clinical Oncology article that reviews the incidence of SCLC over time through use of the SEER (Surveillance, Epidemiologic, and End Results) database. Data points examined include sex- and stage-based differences in the incidence and survival of SCLC patients over time.

The Lancet. Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Accessed November 15, 2022.

This Lancet article reviews the results of the CASPIAN trial, a randomized, controlled, clinical trial. The Trial specifically assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC.

Clinical Lung Cancer. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Accessed November 15, 2022.

This article examines the effects of administering trilaciclib prior to chemotherapy in three randomized, placebo-controlled, double-blind, phase II clinical studies in patients with ES-SCLC.

SpringerNature. BioMed Central. Journal of Hematology & Oncology. Emerging Therapies for Small Cell Lung Cancer. Accessed November 15, 2022.

This Journal of Hematology & Oncology article examines treatment options for SCLC including immunotherapy and small-module TKI drugs.

OncLive® Peer Exchange. Emerging Treatments in SCLC: Bispecific Antibodies. Accessed November 15, 2022.

In this OncLive® video, experts discuss emerging data on treating small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.

OncLive® Peer Exchange. Emerging Treatments in SCLC: Targeting DNA Damage. Accessed November 15, 2022.

In this OncLive® video, Vivek Subbiah, MD, provides an overview of clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

OncLive® Peer Exchange. Emerging Treatments in SCLC: Triplets + Limited-Stage Disease. Accessed November 15, 2022.

In this OncLive® video, Anne Chiang, MD, PhD, reviews the study design of two clinical trials thatadd a third agent to the standard-of-care regimen of chemotherapy plus I/O, and Stephen Liu, MD, who discusses clinical trials in limited-stage disease.

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Clinics and Practice. Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

This article in Clinics and Practice, reviews prior experience and future directions of pembrolizumab in extensive-stage SCLC.

OncLive® Peer Exchange. First-Line Therapy in ES SCLC: CASPIAN. Accessed November 15, 2022.

In this OncLive® video,  Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial, emphasizing implications for long-term benefit of combining platinum chemotherapy with durvalumab.

OncLive® Peer Exchange. First-Line Therapy in ES SCLC: IMpower133. Accessed November 15, 2022.

In this OncLive® video, Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer.

OncLive® Peer Exchange. First-Line Therapy in ES SCLS: KEYNOTE-604. Accessed November 15, 2022.

In this OncLive® video, Vivek Subbiah, MD, examines the phase three KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab.

OncLive® Peer Exchange. Future Directions in ES SCLC. Accessed November 15, 2022.

In this OncLive® video, expert panelists review treatment considerations for asymptomatic brain metastases, progress in biomarker research, and frequency of administering checkpoint inhibitors.

SAGE Journals. Annals of Pharmacology. Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Accessed November 15, 2022.

This study in SAGE Journals looks to determine whether zoledronic acid dosed at every 12 weeks is similar to every four weeks dosing for prevention of skeletal-related events in patients with metastatic lung cancer.

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Journal of Clinical Oncology. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Accessed November 15, 2022.

This study published in the Journal of Clinical Oncology compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage Small Cell Lung Cancer.

OncLive® Peer Exchange. SCLC: Rechallenging With Chemotherapy + I/O. Accessed November 15, 2022.

In this OncLive® video, Anne Chiang, MD, PhD leads an expert panel as they discuss whether to rechallenge with chemotherapy and immunotherapy after progression of small cell lung cancer.

OncLive® Peer Exchange. Single Agent I/O Therapy for Relapsed/Refractory. Accessed November 15, 2022.

In this OncLive® video, Anne Chiang, MD, PhD, leads an expert panel reviewing recent withdrawal of FDA-accelerated approval for nivolumab and pembrolizumab for patients with relapsed extensive-stage small cell lung cancer.

OncLive® Peer Exchange. Treatment After Progression of SCLC: Lurbinectedin. Accessed November 15, 2022.

In this OncLive® video, Vivek Subbiah, MD, reviews  safety and efficacy of  lurbinectedin in patients who have platinum-sensitive relapsed small cell lung cancer.

OncLive® Peer Exchange. Treatment Considerations: Chemotherapy + IO in ES SCLC. Accessed November 15, 2022.

In this OncLive® video, panelists examine the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and review factors to consider when deciding between cisplatin or carboplatin.

Taylor & Francis Online. Journal of Medical Economics. Trilaciclib and the Economic Value of Multilineage Myeloprotection from Chemotherapy-Induced Myelosuppression among Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Chemotherapy. Accessed November 15, 2022.

This Journal of Medical Economics article reviews a study assessing the economic impact of administering trilaciclib, prior to standard first-line chemotherapy, using data from a pivotal Phase II study of trilaciclib in the setting of extensive-stage small cell lung cancer.

VuMedi. Trilaciclib and the Economic Value of Multilineage Myeloprotection From Chemo-Induced Myelosuppression in ES-SCLC Treated With 1L Chemo.

A VuMedi video discussing findings from the study examining the economic impact of using trilaciclib prior to first-line chemotherapy.

International Journal of Cancer. Cancer Therapy and Prevention. Trilaciclib prior to Chemotherapy and Atezolizumab in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial. Accessed November 15, 2022.

This article in the International Journal of Cancer compares treatment with a  placebo ortrilaciclib administered prior to etoposide and atezolizumab  to improve patient experience of receiving treatment for ES-SCLC.

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Update 2021: Management of Small Cell Lung Cancer. Accessed November 15, 2022.

This article provides an overview of recent advances regarding SCLC pathogenesis, subtypes, and treatment development through literature review of key trials. This is not an open access article. Subscription is required to access.

National Institutes of Health (NIH). National Library of Medicine. National Center for Biotechnology Information. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Accessed November 15, 2022.

This manuscript reviews early and ongoing attempts to incorporate immunotherapy to the treatment of SCLC, including those with favorable but preliminary results and those with more definitive positive or negative results.

American Society of Clinical Oncology. Journal of Clinical Oncology. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Accessed November 15, 2022.

This article in the Journal of Clinical Oncology, reviews theIMpower133  a randomized, double-blind, phase I/III study. The study examines adding atezolizumab  to carboplatin plus etoposide for first-line  treatment of extensive-stage small-cell lung cancer.

The Oncologist. Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. Accessed November 15, 2022.

This article in The Oncologist, evaluates disparities, such as health care expenditures, access, and quality in the end-of-life period for patients with lung cancer in the U.S.

Journal of Thoracic Oncology. Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity. Accessed November 15, 2022.

This article in the Journal of Thoracic Oncology, examines whether independent prognostic factors for overall survival in non-small cell lung cancer such as ethnicity, smoking history, socioeconomic, and marital statuses are also applicable to extensive stage small cell lung cancer.

Frontiers in Oncology. Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Accessed November 15, 2022.

This study in Frontiers in Oncology, examines clinical survival outcomes in Black and White patients with stage IV SCLC and demographic, socioeconomic, clinical features, and treatment patterns of the disease.

GO2 For Lung Cancer. GO2 Foundation for Lung Cancer. Small Cell Lung Cancer Resources. Accessed November 15, 2022.

This site provides access to educational materials, support groups, community engagement, and cutting-edge clinical trials.

LUNGevity. Types of Lung Cancer. Small Cell Lung Cancer Resources. Accessed November 15, 2022.

Access free educational information, peer-to-peer mentoring, helpline, support groups, online community, navigation services, and more.

Levine Cancer Institute. Lung Cancer Support Program.

These brief YouTube videos offer practical tips for people living with lung cancer as well as videos to help you exerices your lungs—all you need is a Kazoo.

American Cancer Society

Access free educational resources, helpline, online community, and more.

CancerCare

Access free comprehensive services including case management, counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer.

Cancer Support Community

Access free support groups, online community, educational resources, and toll-free helpline. "As the largest professionally led non-profit network of cancer support worldwide, the Cancer Support Community is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community.

National Institutes of Health. National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ®)– Patient Version. Accessed November 15, 2022.

This patient smart sheet provides information about the treatment of small cell lung cancer. It is meant to inform and help patients, families, and caregivers.

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Small Cell Lung Cancer. Accessed November 15, 2022.

This book presents information from the clinical small cell lung cancer guidelines in an easy to use format for patients. The booklet provides an overview of small cell lung cancer, staging, treatment options, and questions for your doctor to help with treatment decision-making.